Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (1)
Type
Type
Guidance (130)
Quality standard (2)
Guidance programme
Guidance programme
Clinical guidelines (7)
Diagnostics guidance (1)
Health technology evaluations (1)
Interventional procedures guidance (1)
Medical technologies guidance (1)
NICE guidelines (8)
Technology appraisal guidance (119)
Apply filters
Showing 81 to 90 of 132
Sort by
Title
Date
Apply sorting
Keyword or reference number: cancer
Remove Keyword or reference number: cancer filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder
cancer
[TSID12021]
Technology appraisal guidance
TBC
Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck
cancer
[ID6477]
Technology appraisal guidance
1 July 2026
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung
cancer
[ID6399]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial
cancer
after surgery with curative intent [ID6207]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast
cancer
[ID6285]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal
cancer
[ID3853]
Technology appraisal guidance
TBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian
cancer
after 1 or 2 treatments ID6363
Technology appraisal guidance
TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung
cancer
[ID3861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction
cancer
[TSID11861]
Technology appraisal guidance
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal
cancer
[TSID12096]
Technology appraisal guidance
TBC
Previous page
1
…
7
8
Current page
9
10
11
…
14
Page
9
of
14
Next page
Results per page
10
25
50
All
Back to top